Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph nodes.

Trial Details

NCT ID
NCT06445114
Phase
PHASE2
Sponsor
Zachary Zumsteg
Status
RECRUITING
Cancer Type
HPV Positive Head and Neck Cancer
Interventions
  • Cisplatin
Locations (sample)
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Los Angeles, California, United States|34.05223,-118.24368
  • Tarzana, California, United States|34.17334,-118.55397
  • Torrance, California, United States|33.83585,-118.34063

Key Eligibility Criteria

  • AJCC 8th edition T0-3N0-2 p16-positive oropharyngeal (tonsil, base of tongue, glossotonsillar sulcus, soft palate, oropharyngeal wall) squamous cel…
  • For patients with pT0 tumors (unknown primary), there must be at least one metastatic lymph node present in cervical level II.
  • p16 is strongly positive by immunohistochemistry or high-risk HPV is detected by in-situ hybridization.
  • Have undergone or will undergo gross total resection of all known disease in the head and neck via transoral robotic surgery. For patients with cli…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HPV Positive Head and Neck Cancer Trials on Trialify →